Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 784.45

-0.4%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

The Ox

From: Biotech Jim	8/4/2015 8:02:43 AM
	1 Recommendation Read Replies (1) of 3559

Regeneron Reports Second Quarter 2015 Financial and Operating Results (August 4, 2015) - Second quarter 2015 EYLEA® (aflibercept) Injection global net sales increased 50% to $993 million (consisting of $655 million in the U.S. and $338 million in rest of world(1)) versus second quarter 2014 - Second quarter 2015 non-GAAP net income(2) increased 17% to $338 million, or $2.89 per diluted share, versus second quarter 2014 - Raised estimated full year 2015 EYLEA U.S. net sales growth guidance to 45% - 50% over 2014, from the previous guidance of 30% - 35% - Phase 3 pivotal trials for dupilumab in atopic dermatitis fully enrolled files.shareholder.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next